Pluto Biosciences, Inc

GSE114298: Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity

Bulk RNA sequencing

This study reveals a novel strategy to target Tregs in cancer that mitigates autoimmunity by reprogramming their function in tumors to enhance anti-cancer immunity. SOURCE: Walter Eckalbar (walter.eckalbar@gmail.com) - University of California, San Francisco

View this experiment on Pluto Biosciences, Inc